Purchase this article with an account.
Lap Ki Alex Ng, Qi Tan, George Pak Man Cheng, Victor CP Woo, Pauline Cho; Combined atropine with orthokeratology in childhood myopia control (AOK) - A randomized controlled trial. Invest. Ophthalmol. Vis. Sci. 2019;60(9):3899.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To present the initial 6-month results of a two-year randomized control trial, comparing the efficacy of combined 0.01% atropine with Orthokeratology (AOK) versus orthokeratology alone (OK) for myopia control.
This is an examiner-masked, randomized control trial carried out in Hong Kong. Chinese children, aged from 6 to 11 years old, with 1.00 to 4.00 D myopia and astigmatism less than 2.50 D were recruited. They were randomly assigned to AOK or OK groups. In the AOK group, single-dose 0.01% preservative-free atropine was given topically to both eyes every night before ortho-k lens wear. The primary outcome measure was the axial length elongation measured using partial coherence interferometry (IOL master 500).
Thirty subjects were included in the AOK group and 35 in the OK group. The average age was 9.1±1.2 years in AOK and 9.1±1.0 in OK. The OK lens first-fit success rate was 97% and 94% respectively. At the 6-month visit, there were 30 subjects in AOK group and 32 subjects in OK group (3 were terminated from the study due to contact lens intolerance). Axial elongation in AOK group was - 0.02 ± 0.11 mm (- 0.16 – 0.03 mm) and that in OK group was 0.06 ± 0.09 mm (P = 0.0027). Atropine 0.01% ophthalmic solution, when combined with ortho-k lens wear, was well-tolerated in all subjects.
Our initial 6-month result showed that combination of single-dose 0.01% atropine with ortho-k lens wear have an additive effect in slowing axial elongation, when compared with monotherapy of ortho-k alone or 0.01% atropine alone. The combined treatment was well-tolerated.
This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.
This PDF is available to Subscribers Only